Learn More
OBJECTIVES To evaluate the association between bisphosphonate use and the risk of atypical femoral fractures among women aged 65 or older. DESIGN Nested case-control study. SETTING General practice research database in Spain. EXPOSURES Use of oral bisphosphonates before the occurrence of atypical fractures among cases or the corresponding index date(More)
OBJECTIVES To evaluate the association between the long-term use of bisphosphonates and the risk of hip fracture compared to never use among women aged 65 years or older. DESIGN Case-control study nested in a cohort. SETTING General practice research database operated by the Spanish Medicines Agency. PARTICIPANTS Cases of hip fracture were defined as(More)
OBJECTIVES To analyse the prevalence in primary care of use of drugs to treat acidity and ulcers, and to study how prescription of these medicines matches up with indication. DESIGN Crossover study of 1213 clinical histories selected according to simple random sampling. SETTING 6 health centres in Navarra. PATIENTS 370 histories with a record of use(More)
  • J Erviti
  • Anales del sistema sanitario de Navarra
  • 2003
The aim of this study is to analyse the evolution of the global and relative use of medicines recommended for osteoporosis during the period between 1998 and 2002 in Navarra, and their adaptation to present evidence, making reference to the differences in the prescription profile in primary and specialised care. To this end, information is used from all the(More)
PURPOSE To evaluate the framework of drug information produced by public health and regulatory institutions in Europe. MATERIALS AND METHODS We carried out a short survey asking editors of ISDB bulletins of the European region to indicate the main sources of drug information provided by public health and regulatory authorities in their countries, the(More)
Oral anti-diabetic drugs (OADs) have been associated with community-acquired pneumonia (CAP). We aimed to validate the recording of CAP in the Spanish Database for Pharmacoepidemiological Research in Primary Care (BIFAP) for the future evaluation of OAD-CAP association. The incidence rate (IR/1000 person-years) of CAP in type 2 diabetes mellitus (T2DM) was(More)
Background: In January 2014, the EMA's Pharmacovigilance Risk Assessment Committee recommended that strontium ranelate no longer be used for osteoporosis. However, EMA's Committee for Medicinal Products for Human Use decided to restrict its use rather than ban it. Starting from this fact, evidence of drugs for fracture prevention over the last 30 years was(More)